MacroGenics to Present at the 26th Annual ROTH Conference
ROCKVILLE, Md., March 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jon Wigginton, M.D., Senior Vice President, Clinical Development and Jim Karrels, Vice President and Chief Financial Officer, of MacroGenics, are scheduled to present at the 26th Annual ROTH Conference on Monday, March 10, at 10:30 a.m. Pacific (1:30 p.m. Eastern Time).
A live webcast of MacroGenics' presentation may be accessed in the Investor Relations section of the company's website at http://ir.macrogenics.com/events.cfm. MacroGenics will maintain an archived replay of the webcast on its website for 90 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several
strategic collaborations with global pharmaceutical and biotechnology companies. www.macrogenics.com
CONTACT: Jim Karrels, Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, info@macrogenics.com
Karen Sharma, Vice President
MacDougall Biomedical Communications
1-781-235-3060, ksharma@macbiocom.com
Source:
MacroGenics, Inc.
News Provided by Acquire Media
